VitaNova Life Sciences Corporation
VNOV
$4.83
-$2.67-35.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 154.79% | 187.50% | 291.27% | 366.46% | 4,207.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.79% | 187.50% | 291.27% | 366.46% | 4,207.56% |
| Cost of Revenue | 187.53% | 206.14% | 375.78% | 462.90% | -- |
| Gross Profit | 134.23% | 176.30% | 248.48% | 317.18% | 2,545.70% |
| SG&A Expenses | 47.77% | 19.21% | 31.29% | 113.42% | 578.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.32% | 114.47% | 190.24% | 298.16% | 1,376.40% |
| Operating Income | 233.28% | 391.79% | 562.36% | 487.74% | 1,239.05% |
| Income Before Tax | 235.01% | 394.25% | 559.84% | 485.51% | 1,231.75% |
| Income Tax Expenses | 225.05% | 282.39% | 378.85% | 444.84% | -- |
| Earnings from Continuing Operations | 241.46% | 470.63% | 682.88% | 504.19% | 793.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 241.46% | 470.63% | 682.88% | 504.19% | 793.02% |
| EBIT | 233.28% | 391.79% | 562.36% | 487.74% | 1,239.05% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 241.22% | 409.85% | 766.39% | 1,573.77% | 261.73% |
| Normalized Basic EPS | 233.96% | 359.02% | 596.95% | 926.14% | 365.35% |
| EPS Diluted | 241.22% | 409.85% | 766.39% | 1,573.77% | 261.73% |
| Normalized Diluted EPS | 233.96% | 359.02% | 596.95% | 926.14% | 365.35% |
| Average Basic Shares Outstanding | 0.00% | 23.34% | 61.43% | 133.57% | 322.27% |
| Average Diluted Shares Outstanding | 0.00% | 23.34% | 61.43% | 133.57% | 322.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |